Adoptive T-cell transfer in cancer immunotherapy

Immunol Cell Biol. 2006 Jun;84(3):281-9. doi: 10.1111/j.1440-1711.2006.01441.x.


Adoptive T-cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein-Barr virus-associated post-transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self-antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour-evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adoptive Transfer*
  • Humans
  • Immunotherapy, Adoptive*
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology*